Loading clinical trials...
Loading clinical trials...
It has been showed that alkylating chemotherapy, particularly the widely used agent temozolomide, may cause high tumor mutational burden (TMB) in certain tumors by causing inactivating mutations in th...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Uppsala University
NCT06503146 · Sarcoma, Small Cell Lung Cancer or Extrapulmonary Neuroendocrine Cancer (EP-NEC), and more
NCT07284589 · Healthy (Controls), Healthy Volunteers, and more
NCT06981455 · Neuroendocrine (NE) Tumors, Neuroendocrine Tumor GEP Grade 1-3
NCT06717243 · Small Cell Lung Cancer, Large Cell Neuroendocrine (NE) Tumors, and more
NCT07052760 · Solid Tumor Cancer, Castration Resistant Prostate Cancer, and more
Akademiska Sjukhuset
Uppsala
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions